Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Ensysce Biosciences (NASDAQ:ENSC) has announced its upcoming symposium at PAINWeek 2025 on September 3, 2025, focusing on pain management perspectives. The company recently hosted a panel discussion titled 'The State of the Nation in Pain: A Discussion on Analgesics and Their Optimal Uses'.
The panel, moderated by Ensysce's CMO Dr. William Schmidt, included pain medicine experts Dr. Todd Bertoch and Dr. Jeff Gudin. They discussed various analgesics, treatment effectiveness, and advances in pain medicine, including Ensysce's next-generation opioid PF614.
A key finding from the discussion revealed that while new analgesic classes are needed, opioids remain the gold standard for severe pain treatment. The company's development of 'Next Generation' opioids with safety features, including overdose protection through products like PF614 and PF614-MPAR, could potentially offer significant societal benefits.
Ensysce Biosciences (NASDAQ:ENSC) ha annunciato il suo prossimo simposio a PAINWeek 2025 il 3 settembre 2025, focalizzandosi sulle prospettive nella gestione del dolore. L'azienda ha recentemente ospitato una tavola rotonda intitolata 'Lo Stato della Nazione sul Dolore: Una Discussione sugli Analgesici e i Loro Usi Ottimali'.
Il panel, moderato dal CMO di Ensysce, il Dr. William Schmidt, includeva esperti in medicina del dolore come il Dr. Todd Bertoch e il Dr. Jeff Gudin. Hanno discusso vari analgesici, l'efficacia dei trattamenti e i progressi nella medicina del dolore, compreso l'oppioide di nuova generazione PF614 di Ensysce.
Una scoperta chiave emersa dalla discussione ha rivelato che, sebbene siano necessarie nuove classi di analgesici, gli oppioidi rimangono lo standard d'oro per il trattamento del dolore severo. Lo sviluppo da parte dell'azienda di oppioidi 'Next Generation' con caratteristiche di sicurezza, inclusa la protezione da sovradosaggio attraverso prodotti come PF614 e PF614-MPAR, potrebbe offrire potenziali benefici significativi per la società.
Ensysce Biosciences (NASDAQ:ENSC) ha anunciado su próximo simposio en PAINWeek 2025 el 3 de septiembre de 2025, centrado en las perspectivas de manejo del dolor. La compañía recientemente organizó una mesa redonda titulada 'El Estado de la Nación en Dolor: Una Discusión sobre Analgésicos y sus Usos Óptimos'.
El panel, moderado por el CMO de Ensysce, el Dr. William Schmidt, incluyó a expertos en medicina del dolor como el Dr. Todd Bertoch y el Dr. Jeff Gudin. Discutieron varios analgésicos, la efectividad de los tratamientos y los avances en medicina del dolor, incluido el opioide de nueva generación PF614 de Ensysce.
Un hallazgo clave de la discusión reveló que, aunque se necesitan nuevas clases de analgésicos, los opioides siguen siendo el estándar de oro para el tratamiento del dolor severo. El desarrollo por parte de la compañía de opioides de 'Nueva Generación' con características de seguridad, incluida la protección contra sobredosis a través de productos como PF614 y PF614-MPAR, podría ofrecer beneficios significativos para la sociedad.
Ensysce Biosciences (NASDAQ:ENSC)는 2025년 9월 3일 PAINWeek 2025에서 통증 관리 관점에 초점을 맞춘 심포지엄을 개최한다고 발표했습니다. 이 회사는 최근 '통증에 대한 국가의 현황: 진통제 및 그 최적 사용에 대한 토론'이라는 제목의 패널 토론을 주최했습니다.
이 패널은 Ensysce의 최고 의료 책임자(CMO)인 윌리엄 슈미트 박사가 진행했으며, 통증 의학 전문가인 토드 베르톡 박사와 제프 구딘 박사가 포함되었습니다. 그들은 다양한 진통제, 치료 효과 및 통증 의학의 발전, Ensysce의 차세대 오피오이드 PF614 등을 논의했습니다.
토론에서 도출된 주요 발견은 새로운 진통제 클래스가 필요하지만, 오피오이드가 여전히 심한 통증 치료의 금본위제라는 것입니다. PF614 및 PF614-MPAR와 같은 제품을 통한 과다복용 방지 기능을 포함한 '차세대' 오피오이드의 개발은 사회에 상당한 혜택을 제공할 수 있습니다.
Ensysce Biosciences (NASDAQ:ENSC) a annoncé son prochain symposium lors de PAINWeek 2025 le 3 septembre 2025, axé sur les perspectives de gestion de la douleur. L'entreprise a récemment organisé une table ronde intitulée 'L'État de la Nation en Matière de Douleur : Une Discussion sur les Analgésiques et leurs Usages Optimaux'.
Le panel, modéré par le CMO d'Ensysce, le Dr William Schmidt, comprenait des experts en médecine de la douleur tels que le Dr Todd Bertoch et le Dr Jeff Gudin. Ils ont discuté de divers analgésiques, de l'efficacité des traitements et des avancées en médecine de la douleur, y compris l'opioïde de nouvelle génération PF614 d'Ensysce.
Une découverte clé de la discussion a révélé que, bien que de nouvelles classes d'analgésiques soient nécessaires, les opioïdes restent la référence en matière de traitement de la douleur sévère. Le développement par l'entreprise d'opioïdes de 'Nouvelle Génération' avec des caractéristiques de sécurité, y compris la protection contre les surdoses grâce à des produits comme PF614 et PF614-MPAR, pourrait potentiellement offrir des avantages sociétaux significatifs.
Ensysce Biosciences (NASDAQ:ENSC) hat sein bevorstehendes Symposium auf PAINWeek 2025 am 3. September 2025 angekündigt, das sich mit Perspektiven des Schmerzmanagements befasst. Das Unternehmen hat kürzlich eine Podiumsdiskussion mit dem Titel 'Der Stand der Nation im Schmerz: Eine Diskussion über Analgetika und deren optimale Nutzung' veranstaltet.
Das Panel, moderiert von Ensysces CMO Dr. William Schmidt, umfasste Schmerzmediziner wie Dr. Todd Bertoch und Dr. Jeff Gudin. Sie diskutierten verschiedene Analgetika, die Effektivität von Behandlungen und Fortschritte in der Schmerzmedizin, einschließlich des Next-Generation-Opioids PF614 von Ensysce.
Ein zentrales Ergebnis der Diskussion zeigte, dass, während neue Klassen von Analgetika benötigt werden, Opioide nach wie vor den Goldstandard für die Behandlung von schweren Schmerzen darstellen. Die Entwicklung von 'Next Generation'-Opioiden mit Sicherheitsmerkmalen, einschließlich Überdosierungsschutz durch Produkte wie PF614 und PF614-MPAR, könnte potenziell erhebliche gesellschaftliche Vorteile bieten.
- Development of innovative opioids (PF614, PF614-MPAR) with built-in safety features and overdose protection
- Expert validation of market need for new analgesic solutions while confirming opioids as gold standard
- None.
~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~
~ Panel Discussion Posted to Ensysce's Corporate Website ~
SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, announced it will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with experts in the field of pain management. In preparation for this meeting, the company recently hosted a panel discussion entitled "The State of the Nation in Pain: A Discussion on Analgesics and Their Optimal Uses".
The discussion was moderated by Ensysce's Chief Medical Officer, Dr. William Schmidt, Ph.D., and included Dr. Todd Bertoch M.D., from CenExel JBR in Salt Lake City, UT, and Dr. Jeff Gudin, M.D., from the University of Miami School of Medicine, two world-class experts in the fields of anesthesiology and pain medicine. The panel reviewed various analgesics, their use and considerations for effective treatment, and examined current advances in pain medicine including the development of novel analgesic drugs such as PF614, Ensysce's next generation opioid.
Dr Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are one of the few companies aiming to introduce a new, differentiated class of opioids and want to listen to and work with experts who prescribe these medicines to treat severe pain. We also want to understand how the field views our new agents, PF614 and PF614-MPAR, and how they will fit into the patient treatment paradigm, especially with the emerging discipline of multi-modal care. This recent panel discussion was an excellent way to take a pulse on the field of pain medicine as it has evolved over the last year and served as a tool to prepare for our symposium at PAINWeek. A key conclusion from the discussion with these experts was that new classes of analgesics are needed, yet opioids remain the gold standard for treating severe pain. The introduction of our ‘Next Generation' of opioids with safety features including overdose protection could have major societal benefits. We look forward to discussing this in depth at PAINWeek in September."
The panel discussion and highlight clips can be viewed on Ensysce's corporate website here.
PAINWeek is the leading meeting dedicated to the latest science on pain. The website can be viewed here https://conference.painweek.org.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences
View the original press release on ACCESS Newswire
FAQ
When is Ensysce Biosciences (ENSC) hosting their PAINWeek 2025 symposium?
What are the key products Ensysce Biosciences (ENSC) is developing for pain management?
Who were the expert panelists in Ensysce's (ENSC) recent pain management discussion?
What was the main conclusion from Ensysce's (ENSC) expert panel discussion on pain management?
